{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:18:36Z","timestamp":1775665116590,"version":"3.50.1"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1097\/ppo.0000000000000223","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T12:16:25Z","timestamp":1475583385000},"page":"334-341","source":"Crossref","is-referenced-by-count":18,"title":["Immune Therapy for Prostate Cancer"],"prefix":"10.1097","volume":"22","author":[{"given":"Oladapo","family":"Yeku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan F.","family":"Slovin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210203","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.urolonc.2014.10.009","article-title":"Immunotherapy for castration-resistant prostate cancer: progress and new paradigms","volume":"33","author":"Quinn","year":"2015","journal-title":"Urol Oncol"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-015-0122-9","article-title":"Chimeric antigen receptor\u2013engineered T cells for the treatment of metastatic prostate cancer","volume":"29","author":"Hillerdal","year":"2015","journal-title":"BioDrugs"},{"key":"R9-6-20210203","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1586\/14737140.6.9.1163","article-title":"Sipuleucel-T (APC8015) for prostate cancer","volume":"6","author":"So-Rosillo","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00262-012-1317-2","article-title":"Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer","volume":"62","author":"Sheikh","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJMe1006300","article-title":"New therapies for castration-resistant prostate cancer","volume":"363","author":"Longo","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-6-20210203","first-page":"1738","article-title":"Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor","volume":"5","author":"Small","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1158\/1078-0432.CCR-14-2334","article-title":"Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome","volume":"21","author":"GuhaThakurta","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1158\/2326-6066.CIR-14-0073","article-title":"A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T","volume":"2","author":"McNeel","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"R16-6-20210203","first-page":"377","article-title":"Lower baseline PSA predicts greater benefit from sipuleucel-T","volume":"11","author":"Petrylak","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/pcan.2014.21","article-title":"Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T","volume":"17","author":"Small","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1158\/1078-0432.CCR-15-0079","article-title":"A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer","volume":"21","author":"Small","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.urology.2012.10.044","article-title":"Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research","volume":"81","author":"Graff","year":"2013","journal-title":"Urology"},{"key":"R22-6-20210203","first-page":"5800","article-title":"A triad of costimulatory molecules synergize to amplify T-cell activation","volume":"59","author":"Hodge","year":"1999","journal-title":"Cancer Res"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-4-1","article-title":"A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer","volume":"4","author":"DiPaola","year":"2006","journal-title":"J Transl Med"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/13543780902997928","article-title":"Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer","volume":"18","author":"Madan","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"R25-6-20210203","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.juro.2007.05.117","article-title":"Clinical safety of a viral vector based prostate cancer vaccine strategy","volume":"178","author":"Arlen","year":"2007","journal-title":"J Urol"},{"key":"R26-6-20210203","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00262-009-0782-8","article-title":"Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer","volume":"59","author":"Gulley","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"R28-6-20210203","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-010-0927-9","article-title":"Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination","volume":"60","author":"Vergati","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"R29-6-20210203","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.6004\/jnccn.2012.0156","article-title":"Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer","volume":"10","author":"Madan","year":"2012","journal-title":"J Natl Compr Cancer Netw"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00262-014-1524-0","article-title":"A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates","volume":"63","author":"Jochems","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"R31-6-20210203","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"Madan","year":"2012","journal-title":"Lancet Oncol"},{"key":"R32-6-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ccr.2005.01.027","article-title":"Androgen ablation mitigates tolerance to a prostate\/prostate cancer\u2013restricted antigen","volume":"7","author":"Drake","year":"2005","journal-title":"Cancer Cell"},{"key":"R33-6-20210203","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/pros.20906","article-title":"Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization","volume":"69","author":"Koh","year":"2009","journal-title":"Prostate"},{"key":"R34-6-20210203","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R35-6-20210203","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2014","journal-title":"N Engl J Med"},{"key":"R36-6-20210203","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R37-6-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R38-6-20210203","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"R39-6-20210203","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1\u2013positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2015","journal-title":"Lancet"},{"key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/j.seminoncol.2015.02.005","article-title":"The ipilimumab lesson in melanoma: achieving long-term survival","volume":"42","author":"Delyon","year":"2015","journal-title":"Semin Oncol"},{"key":"R41-6-20210203","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti\u2013CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R42-6-20210203","first-page":"4609","article-title":"Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"ASCO Meeting Abstracts"},{"key":"R43-6-20210203","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"R44-6-20210203","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"R45-6-20210203","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","article-title":"Prostate cancer and inflammation: the evidence","volume":"60","author":"Sfanos","year":"2012","journal-title":"Histopathology"},{"key":"R46-6-20210203","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-07-5164","article-title":"Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing","volume":"14","author":"Sfanos","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R47-6-20210203","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1073\/pnas.94.15.8099","article-title":"Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer","volume":"94","author":"Kwon","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R48-6-20210203","doi-asserted-by":"crossref","first-page":"15074","DOI":"10.1073\/pnas.96.26.15074","article-title":"Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte\u2013associated antigen 4 (CTLA-4) blockade immunotherapy","volume":"96","author":"Kwon","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R49-6-20210203","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor\u2013transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"van den Eertwegh","year":"2012","journal-title":"Lancet Oncol"},{"key":"R50-6-20210203","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cam4.371","article-title":"CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations","volume":"4","author":"Camacho","year":"2015","journal-title":"Cancer Med"},{"key":"R51-6-20210203","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"R52-6-20210203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"key":"R53-6-20210203","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"R54-6-20210203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"R55-6-20210203","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"R56-6-20210203","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell\u2013mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"R57-6-20210203","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR-T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR\u2013T-cell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"R58-6-20210203","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo\u2013engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"key":"R59-6-20210203","first-page":"-","article-title":"Abstract C13: phase I trial of anti-PSMA designer T cells in advanced prostate cancer.","volume":"72","author":"Junghans","year":"2013","journal-title":"Cancer Res"},{"key":"R60-6-20210203","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2407-14-30","article-title":"Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice","volume":"14","author":"Hillerdal","year":"2014","journal-title":"BMC Cancer"},{"key":"R61-6-20210203","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11864-016-0406-4","article-title":"CAR-T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia","volume":"17","author":"Singh","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"R62-6-20210203","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti\u2013PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R63-6-20210203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.urolonc.2015.02.007","article-title":"Biomarkers for immunotherapy in genitourinary malignancies","volume":"34","author":"Slovin","year":"2015","journal-title":"Urol Oncol"},{"key":"R64-6-20210203","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"R65-6-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2014.00351","article-title":"Exploiting synergy: immune-based combinations in the treatment of prostate cancer","volume":"4","author":"Burotto","year":"2014","journal-title":"Front Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:22:41Z","timestamp":1620969761000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201609000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000223","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}